SharesGrow 7-Criteria Score
All 7 criteria scored · valuation-related highlighted on this page
Paratek Pharmaceuticals, Inc. (PRTK) .
Criteria proven by this page:
- VALUE (0/100, Fail) — the composite valuation score falls below the 60/100 threshold required to pass.
Overall SharesGrow Score: 46/100 with 2/7 criteria passed.
SharesGrow 7-Criteria Score
~
HEALTH
50/100
Debt-to-Equity & liquidity
→ Health
Valuation Snapshot — PRTK
Valuation Multiples
P/E (TTM)0.0
Forward P/EN/A
PEG RatioN/A
Forward PEGN/A
P/B Ratio0.00
P/S Ratio0.80
EV/EBITDA0.0
Per Share Data
EPS (TTM)$-1.17
Book Value / Share$0.00
Revenue / Share$2.77
FCF / Share$0.00
Yields & Fair Value
Earnings YieldN/A
Dividend Yield0.00%
P/E Ratio & Earnings Yield
Earnings Per Share (EPS) History
| Year |
EPS (Diluted) |
Revenue |
Net Income |
Net Margin |
| 2013 |
$-17.54 |
$1.75M |
$-27.45M |
-1571% |
| 2014 |
$-7.05 |
$4.34M |
$-17.84M |
-410.8% |
| 2015 |
$-4.29 |
$0.00 |
$-70.86M |
- |
| 2016 |
$-5.51 |
$29K |
$-111.64M |
-384951.7% |
| 2017 |
$-3.32 |
$12.62M |
$-89.07M |
-706% |
| 2018 |
$-3.57 |
$17.12M |
$-112.36M |
-656.4% |
| 2019 |
$-3.93 |
$16.54M |
$-128.79M |
-778.5% |
| 2020 |
$-2.63 |
$43.52M |
$-116.26M |
-267.2% |
| 2021 |
$-1.22 |
$120.95M |
$-59.08M |
-48.8% |
| 2022 |
$-1.17 |
$150.79M |
$-63.57M |
-42.2% |
